The company's financial position has weakened significantly, with total assets contracting from $51.1 million in 2023Q4 to $17.9 million in 2026Q1, alongside a shift to negative equity.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 14.96M | 15.08M | 21.59M | 34.47M | 37.75M | 56.89M | 51.82M | 49.03M | 55.49M | 72.79M | 89.49M | 104.38M | 118.37M | 129.55M | 57.32M |
| Cash & Short-Term Investments | 13.09M | 12.99M | 15.31M | 31.06M | 35.35M | 53.87M | 48.23M | 46.88M | 54.47M | 71.75M | 88.11M | 100.63M | 115.3M | 126.91M | 55.13M |
| Cash Only | 8.54M | 12.96M | 15.3M | 20.77M | 28.98M | 32.33M | 46.23M | 34.75M | 5.81M | 3.44M | 3.24M | 10.22M | 5.21M | 95.45M | 24.26M |
| Short-Term Investments | 4.54M | 32K | 10K | 10.29M | 6.38M | 21.54M | 2M | 12.13M | 48.66M | 68.32M | 84.88M | 90.41M | 110.09M | 31.45M | 30.87M |
| Accounts Receivable | 286K | 1.88M | 1.49M | 804K | 803K | 1.17M | 2.17M | 1.21M | 746K | 813K | 1.18M | 3.52M | 1.86M | 2.42M | 1.72M |
| Days Sales Outstanding | 73.79 | 178.28 | 97.32 | 98.41 | 174.98 | 460.76 | 760.88 | 586.52 | 155.86 | 87.77 | 65.58 | 115.31 | 46.76 | 50.32 | 36.86 |
| Inventory | 175K | 210K | 1.82M | 76K | 566K | 92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 60.88 | 18.72 | 278.96 | 18.62 | 227.27 | 43.78 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.42M | -504K | 1.3M | 0 | 32K | 77K | 118K | 47K | 47K | 47K | 47K | 47K | 1M | 0 | 0 |
| Total Non-Current Assets | 2.98M | 4.97M | 18.27M | 16.63M | 18.38M | 19.41M | 20.09M | 22.34M | 3.21M | 4.81M | 6.5M | 8.22M | 9.21M | 7.76M | 7.53M |
| Property, Plant & Equipment | 2.41M | 2.64M | 4.25M | 3.44M | 4.07M | 4.18M | 3.94M | 5.25M | 3.19M | 4.79M | 6.48M | 8.2M | 8.81M | 7.21M | 7.4M |
| Fixed Asset Turnover | 1.77x | 1.46x | 1.31x | 0.87x | 0.41x | 0.22x | 0.26x | 0.14x | 0.55x | 0.71x | 1.01x | 1.36x | 1.65x | 2.44x | 2.31x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 12.2M | 13.17M | 14.14M | 15.21M | 16.14M | 17.07M | 0 | 0 | 0 | 0 | 0 | 45K | 89K |
| Long-Term Investments | 509K | 43K | 82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 382K | 471K | 0 |
| Other Non-Current Assets | 576K | 2.29M | 1.75M | 28K | 74K | 25K | 9K | 9K | 19K | 19K | 13K | 22K | 21K | 28K | 43K |
| Total Assets | 17.95M | 20.05M | 39.86M | 51.1M | 56.13M | 76.3M | 71.92M | 71.36M | 58.69M | 77.6M | 95.99M | 112.59M | 127.59M | 137.31M | 64.86M |
| Asset Turnover | 0.22x | 0.19x | 0.14x | 0.06x | 0.03x | 0.01x | 0.01x | 0.01x | 0.03x | 0.04x | 0.07x | 0.10x | 0.11x | 0.13x | 0.26x |
| Asset Growth % | -149.55% | -49.71% | -21.99% | -8.95% | -26.44% | 6.1% | 0.77% | 21.59% | -24.37% | -19.15% | -14.75% | -11.75% | -7.08% | 111.72% | - |
| Total Current Liabilities | 5.36M | 3.44M | 18.7M | 6.94M | 5.63M | 6.88M | 9.68M | 5.75M | 5.43M | 4.66M | 5.22M | 5.64M | 7.92M | 8.57M | 9.5M |
| Accounts Payable | 463K | 639K | 1.23M | 1.78M | 1.04M | 1.46M | 863K | 1M | 1.01M | 1.11M | 1.33M | 1.77M | 1.98M | 2.01M | 1.42M |
| Days Payables Outstanding | 28.94 | 56.97 | 188.33 | 437.27 | 416 | 696.21 | 548.77 | 1.09K | 255.15 | 142.41 | 86.09 | 78.31 | 74.59 | 72.68 | 54.11 |
| Short-Term Debt | 654K | 0 | 10.37M | 853K | 884K | 974K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 525K | 17K | 683K | 750K | 101K | 264K | 119K | 423K | 1.4M | 620K | 1.09M | 819K | 2.08M | 2.2M | 4.94M |
| Other Current Liabilities | 3.3M | 1.21M | 2.88M | -853K | -884K | -974K | 4.14M | 0 | 0 | 0 | 0 | 0 | 386K | 0 | 0 |
| Current Ratio | 2.79x | 4.38x | 1.15x | 4.96x | 6.71x | 8.27x | 5.36x | 8.53x | 10.22x | 15.61x | 17.13x | 18.51x | 14.95x | 15.11x | 6.03x |
| Quick Ratio | 2.76x | 4.32x | 1.06x | 4.95x | 6.61x | 8.25x | 5.36x | 8.53x | 10.22x | 15.61x | 17.13x | 18.51x | 14.95x | 15.11x | 6.03x |
| Cash Conversion Cycle | 105.73 | 140.04 | 187.96 | -320.24 | -13.74 | -191.67 | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.45M | 4.63M | 6.33M | 15.47M | 15.71M | 6M | 5.36M | 5.4M | 2.96M | 3.56M | 3.47M | 3.2M | 3.58M | 3.99M | 7.1M |
| Long-Term Debt | 0 | 0 | 0 | 10.37M | 10.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 6.68M | 1.48M | 1.91M | 285K | 932K | 1.7M | 1.66M | 2.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 68K | 72K | 90K | 393K | 0 | 0 | 0 | 0 | 31K | 33K | 31K | 26K | 29K | 19K | 11K |
| Total Liabilities | 6.81M | 5M | 25.03M | 22.42M | 21.34M | 12.88M | 15.03M | 11.15M | 8.39M | 8.22M | 8.7M | 8.84M | 11.5M | 12.56M | 16.6M |
| Total Debt | 2.03M | 2.2M | 12.87M | 11.51M | 11.93M | 2.67M | 2.44M | 2.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -6.51M | -10.76M | -2.43M | -9.27M | -17.05M | -29.66M | -43.79M | -31.78M | -5.81M | -3.44M | -3.24M | -10.22M | -5.21M | -95.45M | -24.26M |
| Debt / Equity | 0.25x | 0.18x | 0.87x | 0.40x | 0.34x | 0.04x | 0.04x | 0.05x | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.08x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.27x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -4.40x | -7.05x | -118.91x | -127.67x | -122.78x | -74.73x | -96.42x | -53.08x | -147.39x | -161.45x | -136.06x | -91.90x | -76.28x | -100.24x | -35.12x |
| Total Equity | 7.99M | 11.97M | 14.84M | 28.68M | 34.79M | 63.42M | 56.88M | 60.22M | 50.31M | 69.38M | 87.29M | 103.75M | 116.08M | 124.75M | 48.26M |
| Equity Growth % | -51.8% | -19.3% | -48.27% | -17.55% | -45.14% | 11.49% | -5.54% | 19.7% | -27.49% | -20.52% | -15.87% | -10.62% | -6.95% | 158.49% | - |
| Book Value per Share | 0.82 | 1.52 | 2.60 | 6.28 | 8.44 | 1.55 | 1.56 | 2.34 | 1.95 | 2.70 | 3.43 | 4.10 | 4.63 | 6.32 | 2.62 |
| Total Shareholders' Equity | -2.54M | -82K | -1.45M | 12.05M | 27.93M | 53.65M | 46.05M | 50.14M | 50.05M | 69.38M | 87.29M | 103.75M | 116.08M | 124.75M | 48.26M |
| Common Stock | 708K | 488K | 363K | 286K | 235K | 234K | 200K | 142K | 142K | 142K | 141K | 140K | 140K | 137K | 102K |
| Retained Earnings | -288.43M | -282.56M | -274.07M | -257.59M | -233.71M | -207.07M | -179.28M | -155.9M | -137.79M | -117.03M | -96.19M | -76.6M | -59.39M | -44.86M | -35.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 285.17M | 281.99M | 272.26M | 269.35M | 261.4M | 260.49M | 225.12M | 205.9M | 187.7M | 372.54M | 183.34M | 0 | 0 | 0 | 0 |
| Minority Interest | 10.54M | 12.06M | 16.29M | 16.63M | 6.86M | 9.77M | 10.84M | 10.07M | 253K | 0 | 0 | 0 | 0 | 0 | 0 |
Persistent liquidity depletion risk
As reported in financial statements, Evogene's total assets have declined from $51.1 million in 2023Q4 to $17.9 million in 2026Q1, reflecting a significant contraction in the company's resource base as it continues to burn through capital to support its computational biology research initiatives.
The consistent reduction in total assets suggests that the company is consuming its balance sheet to fund ongoing operational deficits rather than growing its underlying value. This downward trajectory warrants close monitoring, as it limits the company's future flexibility to pivot or invest in new R&D opportunities.
Based on reported figures, Evogene's debt-to-equity ratio has fluctuated significantly, reaching 0.25 in 2026Q1, which indicates that management is utilizing debt as a tactical bridge to manage cash flow gaps rather than as a strategic tool for long-term capital expansion.
While the absolute debt levels appear manageable, the reliance on debt in the context of negative equity suggests a precarious financial position. Investors should consider whether this leverage is sustainable given the lack of consistent, recurring cash flows to service these obligations.
According to recent SEC filings, Evogene's cash position has dwindled to $8.5 million as of 2026Q1, down from $20.8 million in 2023Q4, highlighting a tightening liquidity buffer that may necessitate further dilutive financing to sustain the company's current operational burn rate.
The current ratio of 2.79 provides a superficial appearance of health, but this is heavily influenced by the rapid depletion of cash and the lack of substantial, liquid current assets. The company's ability to maintain operations without further capital raises appears increasingly constrained by this shrinking cash runway.
As evidenced by quarterly filings, Evogene's equity has deteriorated into negative territory, reaching -$2.5 million in 2026Q1, a trend driven by the accumulation of $288.4 million in retained earnings losses that reflect the company's long-term struggle to achieve commercial viability.
The erosion of equity suggests that the company's historical R&D investments have not yet translated into tangible, value-creating assets. This negative equity position may complicate future financing efforts and signals a high degree of risk for existing shareholders regarding potential dilution.
Based on the provided data, the complete removal of $13.2 million in goodwill from the balance sheet by 2026Q1 suggests that previous acquisitions have failed to deliver expected synergies, effectively forcing the company to write down the carrying value of its past strategic investments.
The disappearance of goodwill indicates that the company's historical growth-by-acquisition strategy has not yielded the anticipated long-term benefits. This development serves as a warning that the company's past capital allocation decisions may have been overly optimistic, potentially masking deeper operational challenges.
Quick answers to the most common questions about buying EVGN stock.
As of 2025, Evogene Ltd. (EVGN) had total assets of $20.0M including $15.1M in current assets.
Evogene Ltd. (EVGN) carries total debt of $2.2M, offset by $13.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Evogene Ltd. (EVGN) has total shareholders' equity (book value) of $-0.1M ($1.52 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Evogene Ltd. (EVGN) reported a current ratio of 4.38x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.